Provided by Tiger Trade Technology Pte. Ltd.

YieldMax MRNA Option Income Strategy ETF

34.42
+2.427.56%
Post-market: 34.33-0.0949-0.28%19:57 EDT
Volume:560.47K
Turnover:19.49M
Market Cap:219.60M
PE:- -
High:37.50
Open:31.89
Low:31.89
Close:32.00
52wk High:42.39
52wk Low:13.60
Shares:6.38M
Float Shares:6.38M
Volume Ratio:0.45
T/O Rate:8.78%
Dividend:14.34
Dividend Rate:41.66%
ROE:--
ROA:--
PB:--
PE(LYR):- -

Loading ...

S&P 500 Top and Bottom Performing Stocks at About 12:00 P.m. EDT

Reuters
·
Aug 20

Flash Heard: Why Healthcare is Partying Like It's Late 2020

Dow Jones
·
Aug 20

U.S. Stocks on the MOVE-Marvell, Pilgrim's Pride, ServiceNow

Reuters
·
Aug 19

Top Midday Stories: Treasury Lifts Buyback Cap on Long-Dated Securities; Moderna, Merck Say Melanoma Vaccine Meets Primary Endpoint in Trial

MT Newswires Live
·
Aug 19

Goldman Sachs Adjusts Price Target on Moderna to $120 From $67, Keeps Neutral Rating

MT Newswires Live
·
Aug 19

Why 2026 is Biotech's Comeback Year

Dow Jones
·
Aug 19

Moderna data bode well for Sellas into imminent readout, says Maxim

TIPRANKS
·
Aug 19

Moderna Moves Back Toward Covid-Era Valuation with Latest mRNA Update

Dow Jones
·
Aug 19

Moderna : RBC Raises Target Price to $130 from $45

THOMSON REUTERS
·
Aug 19

Leerink says cancer vaccine win should sustain Merck momentum into fall

TIPRANKS
·
Aug 19

Moderna Short Sellers Face About $4.8 Bln on Paper Losses on Wednesday After Stock Surges to $159, According to Ortex Estimates

THOMSON REUTERS
·
Aug 19

Moderna Short-Sellers Stare at Record One-Day Loss as Shares Surge on Vaccine Data

Reuters
·
Aug 19

Moderna Shares Extend Gains, up More than 150%

THOMSON REUTERS
·
Aug 19

Moderna's Experimental Vaccine Prevents Cancer Recurrence, in 'historic' Win for Personalized Medicine. Its Stock is Soaring.

Dow Jones
·
Aug 19

LIVE Markets-Wall Street Struggles for a Modest Bounce-Back

Reuters
·
Aug 19

Instant VIEW-Moderna-Merck Melanoma Vaccine Data Boosts Outlook, but Analysts Await Full Results

Reuters
·
Aug 19

Moderna rises 113.6%

TIPRANKS
·
Aug 19

Phase 3 Melanoma Success Strengthens Moderna’s Oncology Outlook, But Risk‑Reward Keeps Analyst at Hold

TIPRANKS
·
Aug 19

Early notable gainers among liquid option names on August 19th

TIPRANKS
·
Aug 19

Moderna’s Gain Widens To 150%, MRK Rises More Than 12%, BioNTech Climbs Over 24%

Tiger Newspress
·
Aug 19